Extra Boost for Nuclidium: Financing Round Reaches €115 Million
Basel‑based Nuclidium AG closed an oversubscribed extension of its Series B financing, raising the round to roughly €115 million (about $126 million) or CHF 105 million. Existing backers including Kurma Growth Opportunities Fund, Angelini Ventures and the EIB‑backed Aurea led the round, adding a CHF 26.4 million ($28.5 million) tranche. The capital will accelerate Nuclidium’s copper‑based radiotheranostics, with NU101 for metastatic castration‑resistant prostate cancer and NU201 for metastatic breast cancer slated for Phase I/IIa trials this year, and fund expansion of its global manufacturing network. The raise highlights sustained investor appetite for integrated radiopharma platforms as peers pursue large‑scale acquisitions.
Hansa Data Supports Full Approval Plan for Idefirix
Swedish rare‑immunology firm Hansa Biopharma announced positive topline data from its European post‑authorisation efficacy study of Idefirix (imlifidase) in highly sensitised kidney‑transplant patients. In the 51‑patient trial, 90% achieved one‑year graft‑failure‑free survival, with 92% graft survival and 98% patient survival....
Adcendo Inks MSD Supply Deal to Run ADC-Keytruda Combination Study
Adcendo, a Copenhagen‑based biotech, has signed a supply agreement with MSD for Keytruda to launch a Phase Ib trial of its tissue‑factor‑directed ADC ADCE‑T02 in combination with the checkpoint inhibitor. The study, slated for the second half of the year, will...
The European CDMO Model, Powering Biologics Innovation
European contract development and manufacturing organisations (CDMOs) are becoming pivotal as biologics grow in complexity, and 3PBIOVIAN exemplifies this shift with a pan‑European, end‑to‑end model. The company operates GMP‑certified facilities in Pamplona, Spain, and Turku, Finland, offering microbial, mammalian, viral...
OSE’s Tedopi-Keytruda Combo Clears Phase II Ovarian Cancer Hurdle
French biotech OSE Immunotherapeutics announced positive Phase II data for its cancer vaccine Tedopi combined with Merck's Keytruda in platinum‑sensitive recurrent ovarian cancer. The combination improved median progression‑free survival to 4.1 months versus 2.8 months with best supportive care, cutting the risk of...
Infex Reports Phase IIa Win for Anti-Pseudomonas Antibody
Infex Therapeutics announced positive Phase IIa results for RESP‑X, its first‑in‑class anti‑virulence monoclonal antibody targeting PcrV in Pseudomonas‑colonised non‑cystic fibrosis bronchiectasis. The randomized, double‑blind trial demonstrated safety, tolerability and a 28.8‑day half‑life supporting quarterly dosing. While the study was not powered...
SERB to Pay Hansa €110M Upfront for EU Rights to Kidney Transplant Drug
SERB Pharmaceuticals will pay Hansa Biopharma €110 million (≈$119 million) upfront for exclusive rights to Idefirix across Europe, the Middle East and North Africa. The antibody‑cleaving enzyme, conditionally approved for highly sensitized kidney‑transplant patients, generated €18.7 million (≈$20 million) in 2025 sales but has...
Harbour Posts Preclinical Data on Would-Be Rival to Eli Lilly’s $1.9B Obesity Bet
Harbour BioMed released preclinical data on LET003, an ACVR2A/2B‑targeting monoclonal antibody created with its AI‑enabled Hu‑mAtrIx platform. In mouse and monkey studies the molecule cleared more slowly than comparators and drove a 13.5% increase in lean mass versus a rival...
Millions for Preclinical Immunology: Boehringer Teams Up with Immunitas
Boehringer Ingelheim has signed a licensing deal with US‑based Immunitas Therapeutics that could be worth up to €407.5 million (approximately $445 million). The agreement grants Boehringer global rights to a preclinical antibody designed to selectively eliminate disease‑driving immune cells in chronic inflammatory...
EktaH Links Novel Obesity Drug to Fat Loss, Muscle Retention in Early-Phase Trial
EktaH disclosed early‑phase data for two oral candidates that activate fat‑taste receptors CD36 and GPR120, aiming to treat obesity by restoring lipid sensing. In a four‑week dose escalation study, the CD36/GPR120 agonist NKS‑5 reduced fat mass by 4.30% and modestly...
The DASbox® Mini Bioreactor System: Small Scale. Big Results
Eppendorf’s DASbox Mini Bioreactor System lets researchers run up to 24 parallel bioreactors in a footprint of just 7.5 cm per unit. The platform supports 60‑250 mL working volumes, ideal for cell‑screening, media optimization, and early‑stage process development. Integrated DASware software provides QbD‑focused...
InflaRx Attracts Strong Investor Interest with US Share Offering Turning to Kidney
InflaRx, a German biotech listed on Nasdaq, is raising $150 million via a public offering to fund development of its oral C5a receptor inhibitor izicopan, now focused on severe kidney diseases such as ANCA‑associated vasculitis. The company is shifting from its...
Scarlet Raises £3.2 Million to Advance Lab-Grown Red Blood Cell Therapies
Scarlet Therapeutics announced a £3.2 million seed round (≈$4 million) to move its lab‑grown red blood cell (RBC) platform toward in‑vivo proof of concept. The company uses immortalized cell lines, allowing unlimited scale and consistent product quality compared with donor‑derived approaches. Pre‑clinical...
Switzerland’s Biotech Sector Defies Tough Markets with Record Revenue
Switzerland’s biotech sector posted a record CHF 7.5 billion ($8.3 billion) in revenue for 2025, up from CHF 7.2 billion the year before, driven by more market‑ready products and strong CDMO demand. Capital inflows rose 2.1% to CHF 2.6 billion ($2.9 billion), with privately financed firms leading the...
Macrocycles: Big Is the New Beautiful
Macrocycles are gaining traction as a hybrid drug modality that combines the high specificity of biologics with the oral accessibility of small molecules. Advances in synthetic chemistry, AI‑driven design, and DNA‑encoded libraries now enable rapid exploration of billions of candidates,...